Influenza & Respiratory



This event will tackle the latest issues affecting vaccines for respiratory diseases including influenza, TB, RSV and MERS to stimulate the industry to develop more effective vaccines. Ensure you use this event to make people aware of your expertise around key topics such as universal and seasonal flu, maternal immunization and pandemic preparedness.


Who Attends


• Pharma
• Biotech
• National and International Government
• Non-Profit Organizations
• Academics And Research Institutions


Job Titles


• CMO / Head of Scientific Affairs
• Head of Influenza
• Head of Infectious Disease
• Head of R&D
• Head of Regulatory Affairs
• Head of Manufacturing
• Head of Immunology

Who Should Sponsor?


• Platform Technology Providers
• Biotechs
• Big Pharma
• Logistics / Cold Chain


Influenza and Respiratory Vaccines, Tuesday 16 April 2019

Universal and Pandemic Influenza Vaccines

James Crowe
Influenza and Respiratory Vaccines

Universal flu: are we any closer to finding the “holy “grail”? The Grand Challenge

  • 100 years on from the most severe influenza pandemic in recorded history, what have we learnt that’s translational to a universal solution
  • The multifactorial challenges involved in bringing innovation and improvement to flu products by building more rapid capabilities
  • Newest research in universal influenza vaccines and their potential impact on the flu market

Networking Coffee Break

Dr Luc Gagnon
Influenza and Respiratory Vaccines

Cheetah Pace for Premium Vaccine Clinical Assay Development: FLU HA Case Study

Dr Sean Tucker
Influenza and Respiratory Vaccines

Ph2 oral vaccine for protection against influenza challenge in humans

Dr Sybil Tasker
Influenza and Respiratory Vaccines

Ph2 NasoVAX report, a replication-deficient adenovirus vector technology intranasally delivered

Dr Olga Pleguezuelos
Influenza and Respiratory Vaccines

FLU-v, a broad spectrum influenza vaccine: Efficacy and Immunogenicity


Networking Lunch & Poster Session

Dr Koert Stittelaar
Influenza and Respiratory Vaccines

Building further on Viroclinics Ferret model with novel insights: Transmission of HRSV in Immunocompromised ferrets

  • Demonstration of efficient transmission of human respiratory syncytial virus (HRSV) from immunocompromised ferrets to both immunocompromised and immunocompetent ferrets.
  • Research findings were collected by applying several assays including Sequencing, PCR, Virus Culture/Titration. Furthermore, histo pathological changes of respiratory tissues from donor and contact ferrets were demonstrated by standard and immunohistochemistry.
  • A high transmission rate of HRSV was found and more

RSV Vaccines

Gregory Glenn
Influenza and Respiratory Vaccines

Ph3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization

Peter Kwong
Influenza and Respiratory Vaccines

Structural vaccinology for paramyxoviruses


Networking Coffee Break

Ilse Dieussaert
Influenza and Respiratory Vaccines

GSK’s RSV vaccine pipeline update

Dr Christopher Heery
Influenza and Respiratory Vaccines

Ongoing development of a novel vaccine for Respiratory Syncytial Virus

  • An overview of preclinical, phase 1 data and recent phase 2 results
  • Development aspects unique to RSV and immunologic correlates
  • Potential avenues for next steps in demonstrating vaccine efficacy and receiving regulatory approval
Jon Heinrichs
Influenza and Respiratory Vaccines

Sanofi Pasteur’s RSV prophylactic program


Chair’s Closing Remarks per co-lo and Close of Congress Day 2


Off-site Networking Drinks, Supported by Enesi Pharma

last published: 11/Apr/19 17:05

Influenza and Respiratory Vaccines, Wednesday 17 April 2019

Influenza and Respiratory Vaccines

Chair's opening remarks

Respiratory Infections Strategy & Control

Dr Christopher Petro
Influenza and Respiratory Vaccines

Dupilumab imprints a TH1/Type 1 response and enhances the efficacy of the acellular whooping cough vaccine in mice and infant baboons

Dr Tim Hirst
Influenza and Respiratory Vaccines

A new broad-spectrum vaccine against Streptococcus pneumoniae

Michael Schrader
Influenza and Respiratory Vaccines

MIMIX Flu, is a broadly protective, shelf-stable, self-administered influenza vaccine


Networking Coffee Break


Networking Lunch & Poster Session


Paul Offit

New lessons from old controversies

  • What have we learnt from previous vaccines failures to drive new vaccines forward?
  • Why is there is low uptake on currently available vaccines? E.g. HPV & influenza
  • Examples and case studies from: Lyme & Rota – what does this mean for future vaccine innovation and R&D?
Dr Saad Omer

A framework for a comprehensive maternal immunization platform

  • Evidence for current immunization recommendations
  • Maternal vaccines in development
  • The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels
Dr Timothy Cooke

Chair Closing Remarks and End of Congress

last published: 11/Apr/19 17:05

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071